Charles V. Marcus

Dr. Charles V. Marcus


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Seminars in Nuclear Medicine
Verified
Journal Article
Closed access
CMCharles V. Marcus
Charles V. Marcus
RSRathan M. Subramaniam
Rathan M. Subramaniam

1 September 2021 in Radiologic Clinics of North America
Verified
Journal Article
Closed access
CMCharles V. Marcus
Charles V. Marcus
SSSara Sheikhbahaei
Sara Sheikhbahaei
VSVeeresh Kumar N. Shivamurthy
Veeresh Kumar N. Shivamurthy
GAGreg Avey
Greg Avey
RSRathan M. Subramaniam
Rathan M. Subramaniam

1 August 2020 in American Journal of Roentgenology
Verified
Journal Article
Closed access
CMCharles V. Marcus
Charles V. Marcus
PBPeter Butler
Peter Butler
ABAditya Bagrodia
Aditya Bagrodia
SCSuzanne Cole
Suzanne Cole
RSRathan M. Subramaniam
Rathan M. Subramaniam
OBJECTIVE. The purpose of this article is to review the utility of F-18-fluciclovine PET/CT in the evaluation of recurrent prostate cancer. CONCLUSION. Fluorine-18-labeled fluciclovine PET/CT has shown promise in the evaluation of recurrent prostate cancer. Its performance has been superior to that of other imaging modalities. It has had good diagnostic accuracy, especially in the detection of extraprostatic disease recurrence, and the findings have an impact on treatment planning Gallium-68-labeled prostate-specific membrane antigen PET/CT has also had excellent performance in the detection of biochemically recurrent prostate cancer with detection rates superior to those of fluciclovine PET/CT.

4 March 2022 in PET Clinics
Verified
Journal Article
Closed access
CMCharles V. Marcus
Charles V. Marcus
RSRathan M. Subramaniam
Rathan M. Subramaniam